Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.89 USD
+0.04 (1.23%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.88 -0.01 (-0.35%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
ALLO 2.89 +0.04(1.23%)
Will ALLO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ALLO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALLO
Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
ALLO: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Allogene (ALLO) Stock Stands Out in a Strong Industry
Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss
Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates
Other News for ALLO
Amgen’s Blincyto data send Cullinan higher
Commit To Purchase Allogene Therapeutics At $2.50, Earn 32.6% Annualized Using Options
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
Allogene awarded $15M grant from CIRM to support ALLO-316 development
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation